ArticleCureus2026
Influenza A-Associated Acute Necrotizing Encephalitis With Complete Recovery Following Early Immunomodulatory Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decoding the lung-brain axis in influenza: from pulmonary infection to central nervous system injury.Journal of neuroinflammation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We describe a case of a previously healthy 19-month-old female who experienced rapid neurological deterioration following infection with influenza A (H1N1) and was found to have neuroimaging features characteristic of acute necrotizing encephalitis (ANE), including bilateral thalamic involvement and additional multifocal, symmetric gray- and white-matter lesions. At initial presentation, multiple proinflammatory cytokines were markedly elevated in the peripheral blood. Interestingly, while multiple cytokines were also elevated in cerebrospinal fluid (CSF), interleukin-6 (IL-6) and IL-8 levels were substantially higher in CSF (590 and 1330 pg/ml, respectively) than in serum (118 and 68.2 pg/ml, respectively), providing insights into disease pathogenesis and central nervous system-specific immune activation. The patient was treated in a stepwise manner with multimodal immunomodulatory therapy, including intravenous immunoglobulin (days 1-2), corticosteroids (start day 1), IL-1 receptor antagonist anakinra (start day 2), and plasma exchange (start day 3). Blood cytokine levels declined rapidly with initiation of immunomodulatory therapy. She demonstrated a favorable clinical response with complete neurological recovery, despite an unfavorable ANE severity score of 6 that has historically been associated with high mortality. This case highlights the importance of early recognition of ANE in young children with recent influenza infection, the need for prompt multidisciplinary management, consideration of targeted immunomodulatory therapy, and further investigation of cytokine profiling as a tool to improve diagnosis and guide treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.